著者 中村 豊| 坂口 孝作| 岩崎 良章| 能祖 一裕| 下村 宏之| 松田 浩明| 八木 孝仁| 田中 紀章| 辻 孝夫|
発行日 2001-08-31
出版物タイトル 岡山医学会雑誌
113巻
2号
資料タイプ 学術雑誌論文
JaLCDOI 10.18926/AMO/31032
フルテキストURL fulltext.pdf
著者 Higashi, Toshihiro| Tobe, Kazuo| Asano, Ken-ichiro| Ikeda, Hiroshi| Ohsawa, Toshiya| Iwasaki, Yoshiaki| Nouso, Kazuhiro| Shinji, Noriyuki| Morimoto, Yohichi| Satoh, Yasumasa| Andoh, Masaharu| Araki, Yasuyuki| Tomita, Osamu| Morishita, Hirofumi| Kita, Keiji| Tsuchiya, Takahiro| Morichika, Shigeru| Tanabe, Takahiro| Nagashima, Hideo| Tsuji, Takao|
抄録 <p>The ultrasonographic characteristics of hepatocellular carcinomas (HCC) were investigated. Four typical features of HCCs, "mosaic internal echo pattern", "halo", "lateral shadow" and "posterior echo enhancement", were not recognized in minute HCCs smaller than 2 cm in diameter. These characteristics developed as the tumors grew. Only hypoechoic space-occupying lesions can be considered as small HCCs. In differentiating small HCCs from hypoechoic non-malignant space-occupying lesions in the cirrhotic liver, the ratios of short to long dimensions of the lesions seemed to be important since the ratios of HCCs were significantly larger than those of non-malignant lesions. The fact that 3 hyperechoic small HCCs could not be diagnosed even by celiac arteriography has suggested to us that ultrasonically guided biopsies should be performed in order to differentiate from small hemangiomas. Serum alpha-fetoprotein (AFP) levels of 1/3 of the patients with HCCs were below 100 ng/ml, indicating that it is impossible to detect small HCCs only by measuring serum AFP.</p>
キーワード ultrasonography hepatocellular carcinoma alpha-fetoprotein
Amo Type Article
発行日 1988-06
出版物タイトル Acta Medica Okayama
42巻
3号
出版者 Okayama University Medical School
開始ページ 151
終了ページ 157
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
論文のバージョン publisher
査読 有り
PubMed ID 2456671
Web of Sience KeyUT A1988P034000005
著者 Takeuchi, Yasuto| Ikeda, Fusao| Moritou, Yuki| Hagihara, Hiroaki| Yasunaka, Tetsuya| Kuwaki, Kenji| Miyake, Yasuhiro| Ohnishi, Hideki| Nakamura, Shinichiro| Shiraha, Hidenori| Takaki, Akinobu| Iwasaki, Yoshiaki| Nouso, Kazuhiro| Yamamoto, Kazuhide|
発行日 2013-03
出版物タイトル Journal of Gastroenterology
48巻
3号
資料タイプ 学術雑誌論文
JaLCDOI 10.18926/AMO/30729
フルテキストURL fulltext.pdf
著者 Ohta, Takeyuki| Sakaguchi, Kohsaku| Fujiwara, Akiko| Fujioka, Shin-ichi| Iwasaki, Yoshiaki| Makino, Yasuhiro| Araki, Yasuyuki| Shiratori, Yasushi|
抄録 <p>This study was conducted to develop a simple surrogate index comprised of routinely available laboratory tests to reflect the histological fibrosis stage. Clinical characteristics and laboratory data from 368 and 249 consecutive patients with chronic hepatitis C, a training cohort and a validation cohort, respectively, were retrospectively evaluated. Platelet (Plt) count and albumin (Alb) level contributed to the discrimination of the respective fibrosis stages. We derived the fi brosis index (FI), FI = 8.0-0.01 x Plt (10 multiply 3/microliter) - Alb (g/dl), from a multiple regression model. FI significantly correlated with the histological fibrosis stage in both the initial and validation cohort at p=0.691 and p=0.661, respectively (Spearman's rank correlation coefficient, p&#60;0.0001). The sensitivity and positive predictive value of FI at a cutoff value &#60; 2.10 for predicting fibrosis stage F0-1 were 66.8% and 78.8% in the initial cohort and 68.5% and 63.6% in the validation cohort, respectively. Corresponding values of FI at a cutoff value &#62;- 3.30 for the prediction of F4 were 67.7% and 75.0% in the initial cohort and 70.8% and 81.0% in the validation cohort. The fibrosis index comprised of platelet count and albumin level reflected the histological fibrosis stage in patients with chronic hepatitis C.</p>
キーワード albumin level chronic hepatitis C fi brosis index fi brosis stage platelet count
Amo Type Article
発行日 2006-04
出版物タイトル Acta Medica Okayama
60巻
2号
出版者 Okayama University Medical School
開始ページ 77
終了ページ 84
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
論文のバージョン publisher
査読 有り
PubMed ID 16680183
Web of Sience KeyUT 000237001900002
著者 Nishimura, Mamoru| Takaki, Akinobu| Tamaki, Naofumi| Maruyama, Takayuki| Onishi, Hideki| Kobayashi, Sayo| Nouso, Kazuhiro| Yasunaka, Tetsuya| Koike, Kazuko| Hagihara, Hiroaki| Kuwaki, Kenji| Nakamura, Shinichiro| Ikeda, Fusao| Iwasaki, Yoshiaki| Tomofuji, Takaaki| Morita, Manabu| Yamamoto, Kazuhide|
発行日 2013-01-30
出版物タイトル Hepatology Research
43巻
10号
資料タイプ 学術雑誌論文
JaLCDOI 10.18926/AMO/43825
フルテキストURL 65_1_11.pdf
著者 Kuwaki, Kenji| Nouso, Kazuhiro| Kobayashi, Yoshiyuki| Nakamura, Shinichiro| Ito, Yoichi M.| Iwadou, Shouta| Hagihara, Hiroaki| Yasunaka, Tetsuya| Toshimori, Junichi| Miyatake, Hirokazu| Miyoshi, Kenji| Onishi, Hideki| Miyake, Yasuhiro| Shoji, Bon| Takaki, Akinobu| Shiraha, Hidenori| Iwasaki, Yoshiaki| Kobashi, Haruhiko| Yamamoto, Kazuhide|
抄録 The purpose of this study was to build a prognostic model of hepatocellular carcinoma (HCC) using time-dependent covariates to re-evaluate the prognosis at any stage of the disease. The subjects were consecutive HCC patients who were treated at our institute between 1995 and 2007. We constructed time-fixed and time-dependent prognostic models with a training group (n=336) and compared the prognostic abilities between conventional Cancer of the Liver Italian Program (CLIP) scores, Japan Integrated Staging (JIS) scores, an Okuda classification, and our prognostic models in the testing group (n=227) with the c-index. The time-dependent prognostic model consisted of main tumor size, tumor number, portal vein invasion, distant metastasis, alpha-fetoprotein, des-gamma-carboxy prothrombin (DCP), bilirubin, and albumin and the weighted scores were set for each factor depending on the hazard ratio for the prognosis. The prognostic index was determined by summing the scores. The c-index values for the CLIP scores, JIS scores, Okuda classification, and our time-dependent model were 0.741, 0.727, 0.609, and 0.870, respectively. These results indicate that our time-dependent model can estimate the prognosis of HCC more precisely than traditional time-fixed models and can be used to re-predict the prognosis of HCC.
キーワード hepatocellular carcinoma humans prognosis proportional hazards models time factors
Amo Type Original Article
発行日 2011-02
出版物タイトル Acta Medica Okayama
65巻
1号
出版者 Okayama University Medical School
開始ページ 11
終了ページ 19
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2011 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 21339791
Web of Sience KeyUT 000287620500002
JaLCDOI 10.18926/AMO/52894
フルテキストURL 68_5_263.pdf
著者 Namba, Shihoko| Miyake, Kayoko| Ikeda, Fusao| Hazama, Tomoko| Hitobe, Yu| Yamasaki, Noriko| Shiraha, Hidenori| Takaki, Akinobu| Nouso, Kazuhiro| Iwasaki, Yoshiaki| Yamamoto, Kazuhide|
抄録 Nursing support might help patients with chronic hepatitis C (CHC) remain in good mental and physical condition during interferon (IFN) therapy. However, the effects of nursing support have not been studied adequately in this context. This case-control study evaluated the effects of nursing support during IFN therapy. Twenty-four CHC patients who received pegylated IFN and ribavirin were enrolled. Nurses advised patients on the maintenance of their mental and physical condition at weekly visits, based on the results of written questionnaires. An additional 24 patients who received IFN therapy without nursing support and who were matched for age, sex, platelet count, viral serogroup and IFN regimen were selected with propensity score matching as controls. The patients with nursing support during IFN therapy achieved higher sustained virological responses (79%) than those without nursing support (58%). Adherence to the IFN and ribavirin regimens at 24 weeks of therapy were slightly higher in the patients with nursing support than those without it, but these differences were not statistically significant. Adherence to ribavirin after 24 weeks of therapy was significantly higher in those with nursing support than those without it (93% and 66%, p=0.045). These results suggested that nursing support services could contribute to the virological responses of CHC patients by promoting drug-regimen adherence.
キーワード chronic hepatitis C nursing support interferon therapy
Amo Type Original Article
発行日 2014-10
出版物タイトル Acta Medica Okayama
68巻
5号
出版者 Okayama University Medical School
開始ページ 263
終了ページ 268
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2014 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 25338482
Web of Sience KeyUT 000343269300002
著者 Moritou, Yuki| Ikeda, Fusao| Takeuchi, Yasuto| Seki, Hiroyuki| Nanba, Shintaro| Iwasaki, Yoshiaki| Yamamoto, Kazuhide|
発行日 2014-02
出版物タイトル Journal of Clinical Microbiology
52巻
2号
資料タイプ 学術雑誌論文
JaLCDOI 10.18926/AMO/31685
フルテキストURL fulltext.pdf
著者 Kondo, Junichi| Shimomura, Hiroyuki| Fujioka, Shin-ichi| Iwasaki, Yoshiaki| Takagi, Shinjiro| Ohnishi, Yasuhiro| Tsuji, Hideyuki| Sakaguchi, Kosaku| Yamamoto, Kazuhide| Tsuji, Takao|
抄録 <p>The preS2 region of the hepatitis B virus (HBV) has been reported to have human polymerized albumin receptor (PAR) activity, which correlates with viral replication. Here, we studied the genomic sequence of the preS region from rare patients lacking PAR activity, despite active viral replication. PAR and DNA polymerase activity was identified in 178 HBe antigen-positive HBV carriers, and a significant correlation between 2 markers was shown, except in 2 hepatitis patients lacking PAR activity. Nucleotide sequences of the preS region of HBV from both patients were examined by direct sequencing of PCR products. In one patient, a 45-base deletion was found to overlap half of the putative polymerized human albumin binding site in the preS2 region. In the other patient, a point mutation at the first nucleotide of the start codon of the preS2 region of HBV was found. There was no such genomic change in the 3 control HBV sequences. These results indicate that the preS2 region is necessary for binding of polymerized human albumin, and this is the first report of naturally existing mutant virus with no or low PAR activity.</p>
キーワード hepatitis B virus preS region polymerized albumin receptor genetic mutation genetic deletion
Amo Type Article
発行日 2002-08
出版物タイトル Acta Medica Okayama
56巻
4号
出版者 Okayama University Medical School
開始ページ 193
終了ページ 198
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
論文のバージョン publisher
査読 有り
PubMed ID 12199524
Web of Sience KeyUT 000177382600004
著者 Kubota, Junichi| Ikeda, Fusao| Terada, Ryo| Kobashi, Haruhiko| Fujioka, Shin-ichi| Okamoto, Ryoichi| Baba, Shinsuke| Morimoto, Youichi| Ando, Masaharu| Makino, Yasuhiro| Taniguchi, Hideaki| Yasunaka, Tetsuya| Miyake, Yasuhiro| Iwasaki, Yoshiaki| Yamamoto, Kazuhide|
発行日 2009-09
出版物タイトル Journal of Gastroenterology
44巻
9号
資料タイプ 学術雑誌論文
著者 Shoji, Bon| Ikeda, Fusao| Fujioka, Shin-ichi| Kobashi, Haruhiko| Yasunaka, Tetsuya| Miyake, Yasuhiro| Shiraha, Hidenori| Takaki, Akinobu| Nouso, Kazuhiro| Iwasaki, Yoshiaki| Yamamoto, Kazuhide|
発行日 2010-11
出版物タイトル Journal of Gastroenterology
45巻
11号
資料タイプ 学術雑誌論文
JaLCDOI 10.18926/AMO/31969
フルテキストURL fulltext.pdf
著者 Piao, Cheng-Yu| Fujioka, Shin-ichi| Iwasaki, Yoshiaki| Fujio, Kozo| Kaneyoshi, Toshihiko| Araki, Yasuyuki| Hashimoto, Kuniaki| Senoh, Tomonori| Terada, Ryo| Nishida, Tomohiro| Kobashi, Haruhiko| Sakaguchi, Kohsaku| Shiratori, Yasushi|
抄録 <p>Lamivudine is widely used to treat patients with hepatitis B. However, the outcomes in patients with hepatocellular carcinoma (HCC) treated with lamivudine have not been established. This study was conducted to evaluate the outcomes of lamivudine treatment for patients with HCC using an untreated, matched control group. Thirty patients with controlled HCC orally received lamivudine. As controls, 40 patients with HCC who were not treated with lamivudine and matched for clinical features were selected. The lamivudine-treated and untreated groups were compared with respect to changes in liver function, HCC recurrence, survival, and cause of death. In the lamivudine-treated group, there was significant improvement in the Child-Pugh score at 24 months after starting treatment, while no improvement was observed in the untreated group. There was no significant difference in the cumulative incidence of HCC recurrence and survival between the groups. However, there was a significant difference in the cumulative incidence of death due to liver failure (P= 0.043). A significant improvement in liver function was achieved by lamivudine treatment, even in patients with HCC. These results suggest that lamivudine treatment for patients with HCC may prevent death due to liver failure. Further prospective randomized studies using a larger number of patients are required.</p>
キーワード liver failure Child-Pughscore recurrence survival resistant mutant
Amo Type Article
発行日 2005-10
出版物タイトル Acta Medica Okayama
59巻
5号
出版者 Okayama University Medical School
開始ページ 217
終了ページ 224
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
論文のバージョン publisher
査読 有り
PubMed ID 16286955
Web of Sience KeyUT 000232835600006
JaLCDOI 10.18926/AMO/52139
フルテキストURL 68_1_17.pdf
著者 Moritou, Yuki| Ikeda, Fusao| Iwasaki, Yoshiaki| Baba, Nobuyuki| Takaguchi, Kouichi| Senoh, Tomonori| Nagano, Takuya| Takeuchi, Yasuto| Yasunaka, Tetsuya| Ohnishi, Hideki| Miyake, Yasuhiro| Takaki, Akinobu| Nouso, Kazuhiro| Yamamoto, Kazuhide|
抄録 The impact of hepatic steatosis on interferon therapy for patients with chronic hepatitis C (CHC) has been associated with single-nucleotide polymorphisms (SNP) of IL28B, patatin-like phospholipase domain-containing protein 3 (PNPLA3), and low-density lipoprotein (LDL) receptor. Whether this holds true for Japanese patients, however, remains unresolved. The present study prospectively enrolled 226 Japanese patients with CHC, and investigated the impact of hepatic steatosis and its related SNPs, including rs8099917 of IL28B, rs738409 of PNPLA3, and rs14158 of LDL receptor, on outcomes of peg-interferon and ribavirin therapy. In multivariate logistic regression analysis, significant factors affecting the severity of hepatic steatosis were high body mass index and the minor alleles of IL28B SNP (p=0.020 and 0.039, respectively). The risk alleles of PNPLA3 SNP also showed weak association (p=0.059). Severe steatosis and the minor alleles of IL28B SNP were significantly associated with null or partial virological response in patients with HCV genotype 1, as were female gender, and low LDL cholesterol (p=0.049, and <0.001, respectively). The SNP genotype of PNPLA3 and LDL receptor did not have a significant impact on therapeutic outcomes. With respect to the SNP sites examined, the SNP of PNPLA3 has a weak association with severe hepatic steatosis, but not with the outcome of interferon therapy.
キーワード hepatic steatosis genetic polymorphism interferon HCV
Amo Type Original Article
発行日 2014-02
出版物タイトル Acta Medica Okayama
68巻
1号
出版者 Okayama University Medical School
開始ページ 17
終了ページ 22
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2014 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 24553484
Web of Sience KeyUT 000331592800003
JaLCDOI 10.18926/AMO/52898
フルテキストURL 68_5_291.pdf
著者 Tsuzaki, Ryuichiro| Takaki, Akinobu| Yagi, Takahito| Ikeda, Fusao| Koike, Kazuko| Iwasaki, Yoshiaki| Shiraha, Hidenori| Miyake, Yasuhiro| Sadamori, Hiroshi| Shinoura, Susumu| Umeda, Yuzo| Yoshida, Ryuichi| Nobuoka, Daisuke| Utsumi, Masashi| Nakayama, Eiichi| Fujiwara, Toshiyoshi| Yamamoto, Kazuhide|
抄録 It is not known how the immune system targets hepatitis C virus (HCV)-infected HLA-mismatched hepatocytes under immune-suppressed conditions after orthotopic liver transplantation (OLT). In addition, the relationship between the HCV-specific immune response and IL28B variants as predictors of HCV clearance has not been well-characterized. We determined the IL28B polymorphisms for 57 post-OLT HCV carriers, and we assessed the HCV-specific immune responses by measuring the peripheral blood mononuclear cell-derived HCV-specific interferon-gamma (IFN-γ) response using an enzyme-linked immunospot assay. At 1-3 years after OLT, patients with no active hepatitis showed higher total spots on the immunospot assay. At>3 years after OLT, patients with resolved HCV showed higher levels of core, NS3, NS5A, and total spots compared to the chronic hepatitis patients. The IL28B major genotype in the donors correlated with higher spot counts for NS5A and NS5B proteins at 1-3 years after OLT. In the post-OLT setting, the HCV-specific immune response could be strongly induced in patients with no active hepatitis with an IL28B major donor or sustained virological response. Strong immune responses in the patients with no active hepatitis could only be maintained for 3 years and diminished later. It may be beneficial to administer IFN treatment starting 3 years after OLT, to induce the maximum immunological effect.
キーワード interferon gamma ELISPOT assay single nucleotide polymorphisms dendritic cell CD4 T cell
Amo Type Original Article
発行日 2014-10
出版物タイトル Acta Medica Okayama
68巻
5号
出版者 Okayama University Medical School
開始ページ 291
終了ページ 302
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2014 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 25338486
Web of Sience KeyUT 000343269300006
関連URL http://ousar.lib.okayama-u.ac.jp/metadata/53129
著者 Tatsukawa, Masashi| Takaki, Akinobu| Shiraha, Hidenori| Koike, Kazuko| Iwasaki, Yoshiaki| Kobashi, Haruhiko| Fujioka, Shin-Ichi| Sakaguchi, Kohsaku| Yamamoto, Kazuhide|
発行日 2011-10-21
出版物タイトル BMC Cancer
11巻
資料タイプ 学術雑誌論文
著者 Hanafusa, Tadashi| Shinji, Toshiyuki| Shiraha, Hidenori| Nouso, Kazuhiro| Iwasaki, Yoshiaki| Yumoto, Eichiro| Ono, Toshiro| Koide, Norio|
発行日 2005-01-20
出版物タイトル BMC Cancer
5巻
資料タイプ 学術雑誌論文
著者 Mizutani, Shinsuke| Ekuni, Daisuke| Furuta, Michiko| Tomofuji, Takaaki| Irie, Koichiro| Azuma, Tetsuji| Kojima, Azusa| Nagase, Jun| Iwasaki, Yoshiaki| Morita, Manabu|
発行日 2012-09
出版物タイトル Journal of Clinical Periodontology
39巻
9号
資料タイプ 学術雑誌論文
JaLCDOI 10.18926/AMO/53560
フルテキストURL 69_4_237.pdf
著者 Nanba, Shintarou| Ikeda, Fusao| Fujioka, Shin-ichi| Araki, Yasuyuki| Takaguchi, Kouichi| Hashimoto, Noriaki| Seki, Hiroyuki| Takaki, Akinobu| Iwasaki, Yoshiaki| Yamamoto, Kazuhide|
抄録 The effectiveness of extending treatment duration as response guided therapy was previously reported for chronic hepatitis C (CHC) genotype 1, but is still controversial for genotype 2. The present study is a retrospective cohort study to investigate the effectiveness of extending treatment duration in therapy with pegylated interferon and ribavirin for patients with CHC genotype 2 by focusing on the timing at which patients obtained undetectable HCV RNA. A total of 306 patients who obtained undetectable HCV RNA by week 24 of treatment and completed 24 weeks of treatment were enrolled. Rapid virological response (RVR) to standard therapy was achieved by 122 patients (51オ), and 89オ of them obtained sustained virological response (SVR), while 69オ of non-RVR patients achieved SVR. Non-RVR patients with undetectable HCV RNA at week 8, and insufficient adherence<80オ pegylated interferon and ribavirin during the first 24 weeks, significantly improved their SVR rate by extended therapy. Among patients receiving extended therapy, drug adherences did not differ between SVR and non-SVR patients, indicating that extending treatment duration might compensate for insufficient antiviral effects due to insufficient drug adherences. This finding might be useful in creating a guideline for extending treatment duration for patients with CHC genotype 2.
キーワード hepatitis C virus interferon genotype 2 response-guided therapy
Amo Type Original Article
発行日 2015-08
出版物タイトル Acta Medica Okayama
69巻
4号
出版者 Okayama University Medical School
開始ページ 237
終了ページ 244
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2015 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 26289915
Web of Sience KeyUT 000365519100007
JaLCDOI 10.18926/AMO/31989
フルテキストURL fulltext.pdf
著者 Ishii, Yasushi| Shimomura, Hiroyuki| Ito, Mamoru| Miyake, Masanobu| Ikeda, Fusao| Miyake, Jiro| Fujioka, Shin-ichi| Iwasaki, Yoshiaki| Tsuji, Hideyuki| Tsuji, Takao|
抄録 <p>It has been documented that the serum complement activities measured by hemolytic assay (CH50) are decreased after storage of sera at a low temperature in some patients with chronic hepatitis C. However, the mechanism of this phenomenon has not been identified yet. Here, we tried to elucidate factors involved in the cold activation of complement (CAC). To clarify what pathway is activated in CAC, we measured complement cleavage products after cold storage of sera. C4d increased significantly after 12 h-storage at cold temperatures in 5 CAC (+) sera compared with 5 CAC (-) (P &#60; 0.01) and 3 control sera (P &#60; 0.05), while Bb did not increase in any of the groups. In order to determine whether IgG or IgG complex is necessary for CAC, 8 CAC (+) sera were incubated with Protein G Sepharose gel beads, and all of them retained hemolytic activities to some extent after cold storage. Column chromatography through Superose 6HR of CAC-positive serum identified the fractions containing molecules that induced CAC in normal serum, which were depleted by treatment with protein G Sepharose. In conclusion, CAC in hepatitis C seems to occur via a classical or lectin pathway, and the IgG complex produced in hepatitis C virus infection may be an important factor in inducing CAC, a common extrahepatic manifestation of hepatitis C.</p>
キーワード hepatitis C virus chronic hepatitis complement activation
Amo Type Article
発行日 2001-08
出版物タイトル Acta Medica Okayama
55巻
4号
出版者 Okayama University Medical School
開始ページ 229
終了ページ 235
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
論文のバージョン publisher
査読 有り
PubMed ID 11512565
Web of Sience KeyUT 000170367200005
著者 Matsushita, Hiroshi| Ikeda, Fusao| Iwasaki, Yoshiaki| Seki, Hiroyuki| Nanba, Shintaro| Takeuchi, Yasuto| Moritou, Yuki| Yasunaka, Tetsuya| Onishi, Hideki| Miyake, Yasuhiro| Takaki, Akinobu| Nouso, Kazuhiro| Yamamoto, Kazuhide|
発行日 2014-02
出版物タイトル Journal of Gastroenterology and Hepatology
29巻
2号
資料タイプ 学術雑誌論文